| __timestamp | Dynavax Technologies Corporation | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84580000 | 18516000 |
| Thursday, January 1, 2015 | 86943000 | 34140000 |
| Friday, January 1, 2016 | 84493000 | 51872000 |
| Sunday, January 1, 2017 | 64988000 | 71772000 |
| Monday, January 1, 2018 | 74951000 | 97501000 |
| Tuesday, January 1, 2019 | 62331000 | 118590000 |
| Wednesday, January 1, 2020 | 28607000 | 169802000 |
| Friday, January 1, 2021 | 32228000 | 192507000 |
| Saturday, January 1, 2022 | 46600000 | 199563000 |
| Sunday, January 1, 2023 | 54886000 | 253598000 |
Unleashing the power of data
In the ever-evolving biotech landscape, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Dynavax Technologies Corporation and Xencor, Inc. have demonstrated contrasting strategies in their R&D allocations. From 2014 to 2023, Xencor's R&D expenses surged by over 1,200%, peaking in 2023 with a remarkable $254 million investment. This reflects Xencor's aggressive pursuit of cutting-edge therapies. In contrast, Dynavax's R&D spending showed a more conservative trajectory, with a 35% decrease from its 2014 peak, indicating a strategic shift or potential resource reallocation. These trends highlight the diverse approaches within the biotech sector, where companies balance innovation with financial prudence. As the industry continues to grow, understanding these investment patterns offers valuable insights into future breakthroughs and market dynamics.
Vertex Pharmaceuticals Incorporated or Dynavax Technologies Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.
R&D Insights: How Incyte Corporation and Dynavax Technologies Corporation Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Xencor, Inc.
R&D Insights: How Amneal Pharmaceuticals, Inc. and Dynavax Technologies Corporation Allocate Funds
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.
R&D Insights: How Rhythm Pharmaceuticals, Inc. and Xencor, Inc. Allocate Funds
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Soleno Therapeutics, Inc. and Xencor, Inc.
Dynavax Technologies Corporation or Xencor, Inc.: Who Leads in Yearly Revenue?
R&D Spending Showdown: Evotec SE vs Xencor, Inc.